What first‑line alternative to lisinopril is recommended for an adult patient with hypertension (or heart‑failure with reduced ejection fraction) who is intolerant due to persistent dry cough, angio‑edema, or worsening renal function?

Alternative to Lisinopril for ACE Inhibitor Intolerance

For patients intolerant to lisinopril due to persistent dry cough, switch directly to an angiotensin receptor blocker (ARB)—specifically valsartan or candesartan—which provide equivalent cardiovascular and renal protection without the kininase inhibition that causes cough. 1

First-Line ARB Alternatives by Indication

For Hypertension

• Losartan 50 mg once daily, titrating to 100 mg daily after 2–4 weeks if BP remains ≥140/90 mmHg 1
• Valsartan 80–160 mg once daily or candesartan 8–16 mg once daily are equally effective alternatives 1
• Target blood pressure <130/80 mmHg for most adults 1

For Heart Failure with Reduced Ejection Fraction

• Valsartan 40 mg twice daily, titrating to target dose of 160 mg twice daily 1
• Candesartan 4–8 mg once daily, titrating to target dose of 32 mg once daily 1
• These ARBs have demonstrated mortality and hospitalization benefits equivalent to ACE inhibitors in heart failure 1

Direct Transition Protocol

Switch immediately without a washout period. Start the ARB on the day after the last lisinopril dose—no pharmacologic washout is required because ACE inhibitors and ARBs act on different steps of the renin-angiotensin system. 2

Monitoring After Transition

• Check serum creatinine/eGFR and potassium within 1–2 weeks of starting the ARB 1
• An increase in creatinine up to 50% above baseline (or to 3 mg/dL / 266 µmol/L, whichever is greater) is acceptable 1
• Potassium up to 5.5–6.0 mmol/L is acceptable with careful monitoring 1
• Reassess blood pressure every 2–4 weeks during titration 1

Special Considerations by Intolerance Type

Persistent Dry Cough

• ARBs do not inhibit kininase and have a markedly lower incidence of cough compared to ACE inhibitors 1, 2
• Cough occurs in <1% of ARB users versus 5–10% with ACE inhibitors 1
• Switch directly to an ARB without delay when cough is troublesome and proven ACE inhibitor-related 1

Angioedema

• Exercise extreme caution: Although ARBs have lower angioedema rates than ACE inhibitors, cross-reactivity can occur 1
• Wait at least 6 weeks after discontinuing the ACE inhibitor before starting an ARB in patients with prior angioedema 2
• Consider alternative classes (calcium channel blockers or thiazide diuretics) if angioedema was severe 1
• Never use an ARB in patients with a history of ARB-induced angioedema 2

Worsening Renal Function

• If renal dysfunction occurred with lisinopril (creatinine increase >50% or hyperkalemia >6.0 mmol/L), ARBs carry the same risk because both classes suppress angiotensin II 1
• In this scenario, consider:
  • Calcium channel blockers (amlodipine 5–10 mg daily) as first alternative 1
  • Thiazide-like diuretics (chlorthalidone 12.5–25 mg daily) for hypertension 1
  • Hydralazine 25–50 mg twice daily plus isosorbide dinitrate 20–40 mg three times daily for heart failure, particularly in African American patients 1

Critical Safety Warnings

Absolute Contraindications to ARBs

• Pregnancy: ARBs cause serious fetal toxicity (renal dysfunction, oligohydramnios, skull hypoplasia, fetal death) and are contraindicated in all trimesters 1, 2
• History of angioedema with ARBs 1, 2
• Severe bilateral renal artery stenosis (risk of acute renal failure) 2

Never Combine ARBs with ACE Inhibitors

Dual renin-angiotensin system blockade is Class III: Harm. Combining an ARB with an ACE inhibitor or direct renin inhibitor (aliskiren) increases the risk of hyperkalemia, syncope, and acute kidney injury by 2–3-fold without providing additional cardiovascular benefit. 1, 2

Alternative Non-RAAS Agents

For Hypertension When ARBs Are Also Contraindicated

1. Calcium channel blockers: Amlodipine 5–10 mg once daily (first choice for most patients) 1
2. Thiazide-like diuretics: Chlorthalidone 12.5–25 mg once daily or hydrochlorothiazide 12.5–25 mg once daily 1
3. Beta-blockers (if compelling indication such as coronary disease, post-MI, or atrial fibrillation): Metoprolol succinate 25–200 mg once daily or carvedilol 6.25–25 mg twice daily 1

For Heart Failure When ARBs Are Contraindicated

• Hydralazine 25–50 mg three times daily plus isosorbide dinitrate 20–40 mg three times daily is the only proven alternative for patients who cannot tolerate ACE inhibitors or ARBs 1
• This combination reduced mortality in African American patients with heart failure when added to standard therapy 1
• High pill burden and frequent adverse effects (headache, gastrointestinal complaints) limit tolerability 1

Common Pitfalls to Avoid

• Do not delay switching from lisinopril to an ARB when cough is persistent and troublesome—prolonged cough significantly impairs quality of life and medication adherence 1
• Do not assume all ACE inhibitor side effects will recur with ARBs—only angioedema shows potential cross-reactivity; cough, hyperkalemia, and renal dysfunction have different mechanisms 1
• Do not start with subtherapeutic ARB doses—begin with standard starting doses and titrate to target doses proven in clinical trials 1, 2
• Do not combine an ARB with the previous ACE inhibitor "to bridge therapy"—this is contraindicated and harmful 1